Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.53 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3830424 | 0.85 | POLB (0.80) | POLBLMNAPKMALDH1A1CYP2C9 | |
| SCHEMBL735657 | 0.85 | POLB (0.80) | POLBLMNAPKMALDH1A1CYP2C9 | |
| SCHEMBL7122592 | 0.85 | POLB (0.80) | POLBLMNAPKMALDH1A1CYP2C9 | |
| SCHEMBL31681326 | 0.84 | ALDH1A1 (0.73) | L3MBTL1POLBLMNAPKMALDH1A1 | |
| SCHEMBL1988224 | 0.81 | ALDH1A1 (0.81) | POLBLMNAPKMALDH1A1CYP2C9 | |
| SCHEMBL14470279 | 0.81 | ALDH1A1 (0.75) | L3MBTL1POLBLMNAPKMALDH1A1 | |
| SCHEMBL6805741 | 0.81 | ALDH1A1 (0.81) | POLBLMNAPKMALDH1A1CYP2C9 | |
| SCHEMBL4775470 | 0.81 | L3MBTL1 (0.63) | L3MBTL1LMNAALDH1A1TSHR | |
| SCHEMBL18410347 | 0.81 | LMNA (0.87) | L3MBTL1POLBLMNAPKMALDH1A1 | |
| SCHEMBL4009699 | 0.81 | L3MBTL1 (0.63) | L3MBTL1POLBLMNAPKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645781-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER INC (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | THOMAS RICHARD C | 2007-01-18 | — | — | US | disclosed |
| US-7141588-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1478629-B1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN CO LLC (US) | 2006-10-11 | — | — | EP | disclosed |
| US-6919329-B2 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1478629-A1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | disclosed |
| US-20040044052-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-03-04 | — | — | US | disclosed |
| US-6686355-B2 | TREATING HEART DISEASE, MULTIPLE SCLEROSIS, ARTHRITIS, ATHEROSCLEROSIS, AND OSTEOPOROSIS; ANTICANCER AGENTS | WARNER-LAMBERT COMPANY | 2004-02-03 | — | — | US | disclosed |
| WO-2003072553-A1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
| US-20020156074-A1 | Biphenyl sulfonamides useful as matrix metalloproteinase inhibitors | BARVIAN NICOLE CHANTEL (US) | 2002-10-24 | — | — | US | disclosed |
| EP-1233016-A1 | Biphenyl sulfonamides useful as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2002-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | L3MBTL1 3033/4885POLB 1744/4885LMNA 3385/4885 |
| US-20040044052-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | L3MBTL1 3033/4885POLB 1744/4885LMNA 3385/4885 |
| US-20020156074-A1 | Biphenyl sulfonamides useful as matrix metalloproteinase inhibitors | MMP3, MMP9, MMP13 | L3MBTL1 3815/4885POLB 2749/4885LMNA 4253/4885 |
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | L3MBTL1 3033/4885POLB 1744/4885LMNA 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.